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Abstract
Pre-exposure prophylaxis (PrEP) strategies utilizing anti-retroviral drugs show considerable 
promise for HIV prevention. However there is insufficient pharmacokinetic (PK) data on drug 
concentrations required for protection at the relevant mucosal tissues where the infection is 
initiated. Here we evaluated the utility of a humanized mouse model to derive PK data on two 
leading drugs, the RT inhibitor tenofovir (TFV) and CCR5 inhibitor maraviroc (MVC). Following 
oral dosing, both the drugs and the intracellular active TFV-diphosphate could be detected in 
vaginal, rectal and intestinal tissues. The drug exposures (AUC24hr) were found to be higher in 
vaginal tissue compared to plasma with even higher levels detected in rectal and intestinal tissues. 
The overall trends of drug concentrations seen in humanized mice reflect those seen in the human 
thus establishing the utility of this model complementing the present non-human primate (NHP) 
models for future pre-clinical evaluations of promising HIV PrEP drug candidates.
Introduction
An estimated 34 million people worldwide were living with HIV in 2011 (2013). The same 
year 2.5 million new infections were reported, along with 1.7 million HIV related deaths 
(2013). While the current highly active antiretroviral therapy (HAART) regimens efficiently 
control the infection and delay progression to AIDS, there is no complete cure due to HIV 
viral latency (Ruelas and Greene, 2013). In addition, prolonged therapy can have other 
problems, including drug resistance and drug toxicity (Pennings, 2013). Preventive vaccines 
would be ideal to control the spread of HIV/AIDS, however no success thus far (Excler et 
al., 2014). Therefore, other approaches are urgently needed to confer protection. In this 
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regard antiretroviral (ARV) drug-based pre-exposure prophylaxis (PrEP) strategies present a 
practical preventative alternative (Heneine and Kashuba, 2012; Nicol and Kashuba, 2010; 
Romano et al., 2013). Two types of PrEP strategies are currently being pursued with 
promising results (Heneine and Kashuba, 2012; Nicol and Kashuba, 2010; Romano et al., 
2013). The first involves oral systemic administration of ARVs, while the second consists of 
topical vaginal or rectal application of ARV-containing gels with both strategies designed to 
prevent HIV sexual transmission by mucosal routes. Indeed, field clinical trials had shown 
promising results with the use of reverse transcriptase inhibitor Tenofovir (TFV) as a 
microbicide gel in preventing HIV vaginal transmission whereas TFV alone or in 
combination with Emtricitabine (Truvada) administered orally also provided significant 
protection (Abdool Karim et al., 2010; Grant et al., 2010).
While protection afforded by these above approaches is promising, inconsistencies were 
found regarding the levels of protection in different clinical trials (Abdool Karim et al., 
2010; Baeten et al., 2012; Grant et al., 2010; Karim et al., 2011; Thigpen et al., 2012; Van 
Damme et al., 2012). In the CAPRISA trial, 44% protection was achieved with a TFV 
microbicide gel, whereas in the VOICE trial, which also used a TFV microbicide gel, the 
trial was discontinued before conclusion because of a lack of protection (Abdool Karim et 
al., 2010; McEnery, 2011; van der Straten et al., 2012). In the IPrEx trial, oral administration 
of Truvada showed a 44% reduction in HIV infection in men who have sex with men 
(MSM) (Grant et al., 2010). The FEM-PrEP trial, also with oral Truvada, was stopped early 
due to lack of efficacy in high-risk female population (Van Damme et al., 2012). The TDF2 
study also evaluated oral Truvada in men and women and reported a 63% reduction in HIV 
infection acquisition (Thigpen et al., 2012). The Partners PrEP study, looking at 
serodiscordant couples, showed a 67% reduction in HIV-1 incidence with oral TFV and a 
75% reduction with Truvada (Baeten et al., 2012). Additional clinical trials are being 
conducted in various test populations and results are being awaited (Cohen et al., 2013). The 
above conflicting results with regard to variable levels of protection are attributed to 
differences in ARV dosing regimens, trial designs and target populations, sexual practices 
and behavioral patterns affecting adherence. A major factor that contributes to protection 
against HIV is the proper drug concentration to be reached in the target mucosal tissues, 
such as vaginal and rectal tissue. Tissue drug concentrations are affected by variables such 
as ARV dose, mode and frequency of administration, tissue permeability and protein 
binding, as well as drug half-life. Consequently, pharmacokinetic (PK) studies that focus on 
the mucosal compartments are critical for the future success of PrEP strategies.
Animal models have played crucial role in therapeutic drug development to derive important 
preclinical data (Akkina, 2013; Veazey, 2013). With regard to assessing HIV PrEP strategies 
non-human primates (NHP) models have been extremely useful in setting the stage for early 
human clinical trials (Evans and Silvestri, 2013; Fennessey and Keele, 2013). For example, 
TFV was successfully evaluated as both oral and topical PrEP in rhesus macaque studies 
(Garcia-Lerma et al., 2010; Garcia-Lerma et al., 2008; Nuttall et al., 2012; Parikh et al., 
2009). The HIV entry inhibitor maraviroc (MVC) was evaluated similarly in NHP (Forbes et 
al., 2011; Malcolm et al., 2013). However, a number of limitations are apparent with NHP 
models. First of all, they are expensive and use of large numbers of animals often is not 
feasible. In addition, SIV or SHIV, not HIV itself, must be applied as a challenge virus thus 
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precluding NHP use for testing drugs specifically developed against HIV. In this context, 
humanized mice (hu-mice) with a transplanted human immune system have become 
amenable to test various HIV prevention approaches (Akkina, 2013; Denton and Garcia, 
2011). Two new generation humanized mouse models are currently available. The hu-HSC 
humanized mouse model such as RAG-hu employs engraftment of human hematopoietic 
stem cells (HSC) into newborn immunodeficient (Rag1−/− or Rag2−/−γc−/−) mice whereas 
the BLT mouse model is derived by transplantation of human fetal thymus tissue, liver 
tissue and HSC (Akkina, 2013; Denton and Garcia, 2011). Both models harbor human 
immune cells in mucosal sites such as vaginal and rectal tissue, and are susceptible to HIV 
infection via these routes thus mimicking key aspects of viral mucosal transmission (Berges 
et al., 2008; Denton and Garcia, 2012; Nischang et al., 2012). Both topical and systemic 
PrEP strategies employing ARVs have been successfully tested using these models (Chateau 
et al., 2013; Denton et al., 2011; Neff et al., 2011; Neff et al., 2010). The drugs tested 
include TFV, MVC, RT inhibitor Emticitabine (FTC) and integrase inhibitor Raltegravir 
(RAL). Pharmacokinetic and pharmacodynamic (PK/PD) analyses of ARVs in relevant 
tissue compartments and blood plasma are important to ascertain the relationship between 
the systemic and local concentrations achieved after drug application and to correlate with 
antiviral efficacy (Romano et al., 2013; Thompson et al., 2013). Such data can inform the 
level and duration of effective drug dosing for HIV prevention. While a number of previous 
studies established the utility of humanized mouse models for efficacy testing of new PrEP 
strategies and more recently drug distribution in lymphoid tissues (Chateau et al., 2013; 
Choudhary et al., 2009; Denton et al., 2008; Denton et al., 2014; Denton et al., 2011; Neff et 
al., 2011; Neff et al., 2010), no PK studies using these models in the context of mucosal 
tissues have been described.
Here we evaluated the utility of hu-mice to derive PK data employing two different classes 
of ARVs - TFV and MVC. Our results show that both ARVs can be readily measured in 
blood plasma and mucosal compartments encompassing vaginal, rectal and intestinal tissues. 
The overall drug distribution kinetics in this system were found to be similar to humans thus 
validating this model for future studies employing more complex combinatorial PrEP dosing 
regimens.
Materials and Methods
Generation of humanized mice
Humanized BALB/c Rag1−/− or Rag2−/−γc−/− (Hu-HSC RAG-hu) mice were generated by 
engrafting human fetal liver-derived CD34+ hematopoietic progenitor cells (HPC) as 
previously described (Berges et al., 2008; Berges et al., 2006). Mice were maintained at the 
Colorado State University Painter Animal Center and all studies were approved by the CSU 
Institutional Animal Care and Use Committee (Protocol 11-3153A). Newborn mice were 
preconditioned by irradiating with a sub lethal dose of 350 rads and then injected 
intrahepatically with 0.5–1 ×106 human CD34+ cells. Mice were screened for human cell 
engraftment at 10–12 weeks post-reconstitution. Peripheral blood was collected by tail bleed 
and red blood cells were lysed by the Whole Blood Erythrocyte Lysing Kit (R&D Systems, 
Minneapolis, MN).The white blood cell fraction was stained against the human pan-
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leukocyte marker CD45 using hCD45-R-PE (Invitrogen) and FACS analyzed to determine 
the levels of human cell engraftment as previously reported (Berges et al., 2008; Berges et 
al., 2006). Mice with more than 50% human cell engraftment were used for experiments 
involving hu-mice to assure robust numbers of human cells being present.
Drug administration of antiretrovirals and sample collection
Female mice were administered with either Tenofovir or Maraviroc by oral gavage. Clinical 
formulations of these drugs in tablet form (Maraviroc (Selzentry) 150 mg, Pfizer Labs; 
Tenofovir disoproxil fumarate (Viread) 300 mg, Gilead Sciences), were freshly dissolved in 
sterile PBS prior to oral gavage. Mouse equivalent drug doses were calculated by using an 
interspecies allometric scaling factor of 12.3 to arrive at 61.5 mg/kg and 62 mg/kg doses for 
TFV and MVC respectively. Mice (three or five per group) received either TFV (1.23 mg 
per 20 gram mouse) or MVC (1.24 mg per 20 gram mouse) by oral gavage daily for 5 days. 
Plasma and tissue samples were collected for each drug following the last gavage at 2h, 8h, 
and 24h for TFV and at 4h, 12h and 24h for MVC. In addition, 48h plasma samples were 
collected for one group each of treated animals. All samples except 48h blood plasma were 
terminal and were collected during mouse necropsies. Tissue samples collected after drug 
administration consisted of vaginal, rectal and intestinal tissue samples. Tissue and plasma 
samples were snap frozen in liquid nitrogen within five minutes from the time of tissue 
collection. For negative controls, plasma and tissue samples were collected from untreated 
mice and were processed using the protocols described above. Samples were stored at 
−80°C until drug measurements.
Measurement of drug concentrations in plasma and tissue samples
Quantification of analytes was similar to previously published methods (Brown et al., 2011). 
Briefly, quantification of TFV concentrations in plasma was performed by protein 
precipitation and LC-MS/MS analysis with an isotopically-labeled internal standard (13C 
TFV). TFV was eluted from a Waters Atlantis T3 (100 × 2.1mm, 3μm particle size) 
analytical column and an API-5000 triple quadrupole mass spectrometer (AB Sciex, Foster 
City, CA) was used to detect the analytes. Data were collected using AB Sciex Analyst 
Chromatography Software (Analyst version 1.6.1). The dynamic range of this assay was 
1-1000 ng/mL using a 1/concentration2 weighted linear regression.
For measuring concentrations in mucosal tissues, TFV and TFV-DP was extracted from 
tissue homogenate by protein precipitation with isotopically-labeled internal standards (13C 
TFV and 13C TFV-DP). TFV was eluted from a Waters Atlantis T3 (100 × 2.1mm, 3μm 
particle size) analytical column, and TFV-DP was eluted from a Thermo Biobasic AX (50 × 
2.1mm, 5μm particle size) analytical column. An API-5000 triple quadrupole mass 
spectrometer was used to detect all analytes. Data were collected using AB Sciex Analyst 
Chromatography Software (Analyst version 1.6.1). The dynamic range of this assay was 
0.3-300 ng/mL of homogenate for each compound using a 1/concentration2 weighted linear 
regression. Concentrations were ultimately converted into ng/mg (TFV) or fmol/mg (TFV-
DP) tissue for final reporting.
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To measure drug concentrations in plasma, MVC was extracted from samples using solid 
phase extraction with Varian BondElut C-18, 100 mg, 1CC cartridges. Plasma samples were 
quantified against the internal standard, alprazolam, on an Agilent 1200 series HPLC system 
using a Zorbax Eclipse XDB (50 × 4.6mm, 1.8μm particle size) analytical column. An 
Agilent 1100 MSD was used to detect the analyte and internal standard. The dynamic range 
of this assay was 1-1000 ng/mL.
For quantification from mucosal tissues, MVC was extracted from tissue homogenates using 
protein precipitation with the internal standard alprazolam. This resulting extract was 
analyzed on an Agilent 1200 series HPLC system using a Zorbax Eclipse XDB (50 × 
4.6mm, 1.8μm particle size) analytical column. An Agilent 1100 MSD was used to detect 
the analyte and internal standard. The dynamic range of this assay was 0.007-7 ng/mg.
Statistical analysis
GraphPad Prism version 5 (GraphPad Software, USA) software was used for data analysis, 
figure generation, calculation of PK parameters and statistical analysis. PK data for TFV, 
TFV-DP and MVC in hu and non-hu mice were compared using Mann-Whitney two-tailed 
test. P values <0.05 were considered as significant. Measures of central tendency were 
expressed as median and inter-quartile range (IQR 25th, 75th percentile).
Results
TFV and TDP concentrations in plasma and mucosal tissue compartments
To compare the differential drug distribution and accumulation, TFV concentrations were 
measured in plasma and mucosal tissue compartments namely, vaginal, rectal and intestinal 
tissues at 2, 8, 24h post-last dose. In addition, plasma concentrations were also determined at 
48h. The composite pharmacokinetic data on drug concentrations at various time points in 
different tissue compartments and plasma of hu-mice are presented in Fig 1 A1 whereas the 
data for individual hu-mice (5 mice per time point) for each of the compartments at different 
times are presented in Fig 1 B1-E1. Similarly, composite pharmacokinetic data and data for 
individual non-hu mice (3 mice per time point) are presented in Fig 1 A2 and Fig1 B2-E2, 
respectively. Data on TFV Cmax, Tmax, half-life (t1/2) and area under the curve (AUC) are 
depicted in Table 1 for both hu and non-hu mice.
TFV was easily detected in all compartments at all time points (Fig 1 A-E). In hu-mice, 
highest concentrations in plasma were detected at 2h post dosing (Cmax 1,990 ng/ml) with a 
terminal elimination phase occurring by approximately 24h. The AUC48h for plasma was 
11,251 ng*h/ml. The median t1/2 in plasma was 17h. In vaginal tissues, Cmax was at 2h 
(729 ng/g) with a gradual elimination by 24h. Vaginal tissue AUC24h was 14,946 ng*h/g 
and TFV concentration in this tissue compartment was higher than in plasma at 8h and 24h. 
Half-life of TFV in vaginal tissue was 9h. Rectal tissue Cmax was 56,732 ng/g at 2h with an 
AUC24h of 1×106 ng*h/g and t1/2 of 13.5h. In intestinal tissue, Cmax was 74,677 ng/g at 2h. 
The AUC was 1.43×106 ng*h/g and tissue t1/2 was 13.9h. The overall TFV exposure 
indicated by AUC24h was the highest in intestinal tissue followed by rectal tissue, vaginal 
tissue and plasma. The AUC24h tissue:plasma ratios for TFV were 1.5 for vaginal, 99 for 
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rectal and 141.7 for intestinal tissue. TFV exhibited higher exposures in rectal and intestinal 
tissue as a group, with concentrations one to two logs higher compared to vaginal tissue and 
plasma at all time points analyzed (Fig 1, Table 1). Half-life values of 13.5h and 13.9h in 
rectal and intestinal tissue respectively suggest similar elimination kinetics from these two 
tissues with slower elimination rate compared to vaginal tissue (t1/2 9h). In comparative 
experiments using non-hu mice, highest TFV concentrations in plasma were also detected at 
2h post dosing (median Cmax 1,550 ng/ml) with a terminal elimination phase by 24h. The 
AUC48h for plasma was 17,278 ng*h/ml. The median t1/2 in plasma was 15h. In vaginal 
tissues, Cmax was at 8h (785 ng/g) with a gradual elimination by 24h. Vaginal tissue 
AUC24h was 9,671 ng*h/g and TFV concentration in this tissue compartment was lower 
than in plasma at 2h and similar to plasma at 8h and 24h. Half-life of TFV in vaginal tissue 
was 6.3h. Rectal tissue Cmax was 76,520 ng/g at 8h with an AUC24h of 1.3 ×106 ng*h/g and 
t1/2 of 53h. In intestinal tissue, Cmax was 50,334 ng/g at 8h. The AUC was 1×106 ng*h/g 
and t1/2 was 61.6h. The overall TFV exposure in non-hu mice, indicated by AUC24h was the 
highest in rectal tissue followed by intestinal tissue, plasma and vaginal tissue. The AUC24h 
tissue:plasma ratios for TFV in non-hu mice were 0.7 for vaginal, 95 for rectal and 77.5 for 
intestinal tissue. As in hu-mice, non-hu mice TFV showed higher exposures in rectal and 
intestinal tissue as a group, with concentrations one to two logs higher compared to vaginal 
tissue and plasma (Fig 1, Table 1). Higher half-life values of 53h and 61.6h in rectal and 
intestinal tissue respectively were seen in non-hu-mice whereas the t1/2 6.3h seen in vaginal 
tissue was lower than that in hu-mice. The plasma TFV PK values between the hu and non-
hu mice at some time points were found to differ significantly (p<0.05) unlike in issues.
The prodrug TFV is metabolized into its active form TFV-DP intracellularly in HIV target 
tissues and cell populations. Accordingly, the levels of TFV-DP were measured in different 
mucosal tissues (Fig 2 and Table 1). In hu-mice, the TFV-DP Cmax was at 2h in rectal 
tissues (604ng/g) and its AUC24h was 70,194ng*h/g. The t1/2 of TFV-DP in rectal 
compartment was 22.2h. In intestinal tissue TFV-DP Cmax was 8,841 ng/g at 8h whereas 
the AUC24h was 172,167 ng*h/g. The intestinal TFV-DP t1/2 was 3.5h. The TFV-DP 
concentrations could not be measured in vaginal tissues consistently as it was detected only 
once each at 2h and 24h. This is in line with difficulties noted in detection of low TFV-DP 
concentrations in previous human studies (Brown et al., 2011; Vourvahis et al., 2008). 
Overall, the intestinal TFV-DP exposure was found to be higher than in the rectal 
compartment indicated by the AUC24h intestinal:rectal tissue ratio of 2.45. TFV-DP 
concentrations were also assessed in non-hu-mice for comparison. The TFV-DP Cmax was 
at 24h in rectal tissue (198 ng/g) and its AUC24h was 3,188 ng*h/g. The t1/2 of TFV-DP in 
rectal compartment could not be calculated due to no elimination seen at 24h. In intestinal 
tissue, Cmax was 119 ng/g at 8h, the AUC24h was 2,414 ng*h/g and the t1/2 was 45.3h. 
Overall, in non-hu mice the rectal TFV-DP exposure was found to be higher than in the 
intestinal compartment indicated by the AUC24h. Similar to that in hu-mice above, TFV-DP 
could not be detected in vaginal compartment. TFV-DP PK differences in hu vs. non-hu 
mice were statistically significant (p<0.05) at all time points in both rectal and intestinal 
compartments with the exception of 2h in the intestinal tissue.
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MVC concentrations in plasma and mucosal tissue compartments
The HIV entry inhibitor MVC acts extracellularly by interfering with viral binding to the 
CCR5 co-receptor. In the first set of experiments, non-hu mice were used (5 per each time 
point) whereas in the second set of experiments hu-mice (3 per time point) were used to 
determine if any differences exists between the PK values. The drug concentrations were 
measured in plasma and vaginal, rectal and intestinal mucosal tissue compartments at 4, 12, 
24h post-last dose. In addition, plasma concentrations were also determined at 48h. The 
composite PK data on MVC drug concentrations at various time points in different tissue 
compartments and plasma are presented in Fig 3A1 (hu-mice) and 3A2 (non-hu-mice), 
whereas the data for individual mice for each of the compartments are presented in Fig 3 
B1-E1 (hu-mice) and Fig 3 B2-E2 (non-hu-mice). PK parameters Cmax, Tmax, t1/2 and 
AUC are shown in Table 2.
MVC was detected in all compartments at all time points analyzed. For non-hu mice, highest 
concentrations in plasma post-last dose were detected at 4h (Cmax 113 ng/ml). The AUC48h 
for plasma was 3,280 ng*h/ml. The composite t1/2 in plasma was 20.1 hrs. In vaginal tissue 
Cmax was at 4h (1,764 ng/g) with a gradual elimination up to 12h. Vaginal tissue AUC24h 
was 11,239 ng*h/g and MVC was detected at higher concentrations than in plasma at 4 h, 
12h and 24h. The t1/2 of MVC in vaginal tissue was 3.7h. Rectal tissue MVC kinetics was 
characterized by Cmax of 3,785 ng/g at 4h, AUC24h of 69,301 ng*h/g and t1/2 of 2.9h. In 
intestinal tissue MVC Cmax was 18,194 ng/g at 4h, AUC24h 134,883 ng*h/g and t1/2 was 
2.7h. The overall MVC exposure, indicated by AUC24h was the highest in intestinal tissue 
followed by rectal tissue, vaginal tissue and plasma. The AUC24h tissue:plasma ratios for 
MVC were 3.65 for vaginal, 22.5 for rectal and 43.8 for intestinal tissue.
With regard to PK of MVC in hu-mice versus non-hu mice, the overall tissue to plasma 
distribution trends were similar, with intestinal tissue showing the highest exposure 
(AUC24h 140,159 ng*h/g), followed by rectal tissue (AUC24h 32,690 ng*h/g), vaginal tissue 
(AUC24h 2,461 ng*h/g) and plasma (AUC24h 488.6 ng*h/ml, AUC48h 755 ng*h/ml), 
Concentration of MVC at 4h (Cmax) in hu-mice was similar to that in non-hu mice in 
plasma. The MVC concentrations in rectal and intestinal tissues were higher in hu vs. non-
hu mice. Significant difference was seen in plasma wherein the t1/2 was 20 times lower in hu 
vs. non-hu mice (1h vs. 20h), while the t1/2 in tissue compartments were slightly lower. 
Also, lower drug exposure (AUC24h) was seen in hu-mice, with the exception of intestinal 
tissue. However, the observed differences in drug concentrations between hu-mice and non-
hu mice were not found to be statistically significant (Mann-Whitney two-tailed test) except 
at 4h for intestinal tissue (p <0.05) and 12h for vaginal tissue (p <0.05).
Discussion
Nearly all present PrEP strategies employ currently approved ARTs for HIV prevention 
(Thompson et al., 2013). However, the doses being used for treating the patients do not 
accurately represent preventive doses necessary for full protection against HIV. Therefore, 
protective drug concentrations at the mucosal transmission target sites such as vaginal and 
rectal tissue must be defined to inform optimal dosing. Derivation of this much needed data 
by experimental studies will represent a significant advancement in the PrEP arena.
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Here we utilized a humanized mouse model (RAG-hu) susceptible to HIV mucosal 
transmission to assess the drug concentrations following oral dosing with two leading PrEP 
candidates with different modes of action, RT inhibitor TFV and entry inhibitor MVC. Since 
concurrent measurements after single dosing may under or overestimate true tissue 
exposures due to different distribution characteristics in tissues compared with plasma, we 
measured drug concentrations after multiple dosing at steady state kinetics (Thompson et al., 
2013). Our results showed that both TFV and MVC can be readily measured in blood 
plasma, vaginal, rectal and intestinal tissues. While there were number of previous studies in 
the human, this is the first experimental study that simultaneously measured the respective 
drug concentrations in multiple mucosal tissues to correlate their values with those in plasma 
(Romano et al., 2013; Thompson et al., 2013).
Previous studies on TFV in hu-mice showed protection against HIV vaginal challenge 
following sytemic and topical drug application (Chateau et al., 2013; Denton et al., 2008; 
Denton et al., 2011). Here with oral dosing, peak concentrations of TFV were detected at 2h 
after last dose in each of the compartments tested with a terminal elimination phase at 
24-48h. The TFV half-life in blood plasma in hu-mice was comparable to that seen in an 
earlier human trial (Kearney et al., 2004). The overall drug exposure determined by 
AUC24hr for TFV in vaginal tissue was found to be 1.5 higher than in blood plasma and two 
logs higher than in blood plasma in rectal and intestinal tissue. This is further illustrated by 
the tissue: plasma AUC24h ratios (T:P ratio) (Fig 4), which were 1.5, 99.0 and 141.7 for 
vaginal, rectal and intestinal tissues respectively, indicating significantly higher drug 
exposure in vaginal and rectal tissues relative to plasma. This observed differential 
accumulation in various tissues is in agreement with the data from multiple human studies 
and could be due to multiple factors that include distinct mucosal expression and 
localization of drug transporters (Nicol et al., 2013; Romano et al., 2013; Thompson et al., 
2013).
Post-uptake, the prodrug TFV is converted intracellularly to its pharmacologically active 
form TFV diphosphate (TFV-DP) inhibiting HIV-RT. As seen with it's prodrug, the TFV-
DP exposure was also higher in intestinal tissue than in rectal tissue as depicted by higher 
AUC24h (172,167 ng*h/g vs. 70,194 ng*h/g) and T:P ratio (141.7 vs. 99). In contrast, the 
half-life of TFV-DP was higher in rectal tissue (22.2h) compared to the intestinal tissue 
(3.5h). Differences in TFV-DP concentrations in rectal and intestinal compartments could be 
due to distinct expression and activity levels of native kinases needed for TFV to TFV-DP 
conversion, and/or differences in tissue expression of drug transporters, in addition to other 
factors influencing the PK of the prodrug TFV (Nicol et al., 2013; Romano et al., 2013; 
Thompson et al., 2013).
Consistent with human studies, higher concentrations of TFV were seen in hu-mouse 
mucosal tissues compared to blood plasma (Dumond et al., 2007; Kwara et al., 2008; 
Vourvahis et al., 2008). The overall TFV tissue exposures were also similar to that in the 
human as depicted by AUC24h tissue:plasma ratios in vaginal, rectal and intestinal tissues 
(Patterson et al., 2011). Sustained TFV and TFV-DP concentrations were seen in the rectal 
compartment similar to a previous human study (Patterson et al., 2011). Long lasting 
intracellular TFV-DP levels seen in hu-mice are also akin to those seen in another previous 
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human trial (Hawkins et al., 2005). The extended half-life seen in the rectal tissue is 
advantageous for protection in MSM and this was documented in iPrEX study wherein it 
was found that individuals that did not fully comply with daily recommended dosing were 
still protected from HIV infection (Grant et al., 2010). These findings taken together suggest 
that overall, the relative PK trends of TFV and its active metabolite TFV-DP in hu-mice are 
similar to that seen in human studies and clinical trials. Moreover, the hu-mice data further 
confirm the favorable PK profile of TFV for its use as a PrEP agent.
With regard to the PK profiles of TFV and TFV-DP in hu- versus non-hu mice, while the 
overall AUC24h trends were similar with drug concentrations being higher in intestinal, 
rectal tissues than in plasma, differences were also noted in tissue exposure levels, Tmax 
and t1/2. For example, the TFV AUC24h tissue:plasma ratios in vaginal and intestinal tissue 
of hu-mice were 2 fold higher compared to non-hu mice whereas the t1/2 was longer in rectal 
and intestinal tissue of non-hu mice (53h and 61.6h, respectively) relative to that in hu-mice 
(13.5h and 13.9h). With TFV-DP, one to two log higher AUC24h was seen in rectal and in 
intestinal tissues of hu-mice whereas it's t1/2 was longer in non-hu mice in both intestinal 
(45.3h versus 3.5h) and rectal (no elimination phase was detected by 24h, compared to 22.2h 
t1/2 in hu-mice) compartments compared to hu-mice (Table 1). While not entirely clear, the 
observed PK differences between hu- versus non-hu mice can be partly attributed to the 
absence of circulating lymphoid cell population, and thus drug clearance in the blood 
compartment as well as the mucosal tissues of non-humanized mice.
With respect to the entry inhibitor MVC, we have previously shown that its oral 
administration at allometric dosing levels is fully protective against HIV vaginal challenge 
in hu-mice (Neff et al., 2010). MVC exerts its antiviral action extracellularly in contrast to 
the RT inhibitor TFV which gets converted to its active form intracellularly. Therefore, in 
our initial experiments we analyzed MVC concentrations in non-hu mice. Maximum MVC 
concentrations were reached at 4h in plasma and in all the mucosal tissues. The highest 
exposure to MVC was seen in intestinal tissue (AUC24h T:BP ratio of 43.8), followed by 
rectal and vaginal tissue (AUC24h ratios of 22.5 and 3.6) The PK trends seen here were 
comparable to those in human studies(Brown et al., 2011; Dumond et al., 2009). As 
indicated by AUC24h tissue:plasma ratios, there were higher exposures in vaginal and rectal 
tissue compartment to that in blood plasma, similar to that seen in previous human clinical 
trials (Brown et al., 2011; Dumond et al., 2009). In addition, blood plasma Tmax, 
elimination rate and AUC12h were similar to those found in human studies (Abel et al., 
2008; Dumond et al., 2009). Sustained high rectal drug concentrations up to 12h correlated 
well with those found in an earlier human study (Brown et al., 2011).
We next determined the MVC pharmacokinetics in hu-mice to see if any differences exist 
when compared with non-hu mice. Similar to the results seen in non-hu mice, maximum 
drug concentrations were reached at 4h in all compartments analyzed. Higher drug exposure 
(AUC24h) was also detected in rectal and intestinal tissues compared to vaginal tissue. 
Hower a significant difference was the much shorter half-life seen in blood plasma of hu-
mice versus non-hu mice (1h vs. 20h). This could be attributable to MVC binding to the 
CCR5 co-receptor on human cells in the blood and tissue compartments of hu-mice. AUC24h 
in plasma, vaginal and rectal tissues in non-hu-mice were found to be higher than in hu-mice 
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most likely due to the absence of human cells that would have sequestrated most of the drug 
in the blood cellular compartment. Higher tissue:plasma AUC24h ratios were seen in hu-
mice compared to non-hu mice for all tissues (Fig 5). This is not unexpected due to lower 
plasma MVC half-life seen in hu-mice. Relative to that seen in human studies, the AUC24h 
tissue:plasma ratios were found to be higher in hu-mice. For vaginal tissue, MVC AUC24h 
VT:BP ratio was 5 in hu-mice compared to 1.9 seen in the human whereas in rectal tissue, 
the RT:BP AUC ratio was 66.9 relative to the 8-26 range seen in the human. Nevertheless, 
the overall MVC exposure trends of higher drug concentrations seen in mucosal tissues 
versus blood plasma are similar between hu-mice and the human. The vaginal concentration 
of MVC necessary for full HIV prevention in human clinical studies is not currently known. 
Therefore the concentrations measured in hu-mice wherein MVC was shown to be fully 
protective against HIV vaginal challenge should inform future dosing strategies in the 
human (Neff et al., 2011). The overall excellent oral bioavailabilty and high genital tract 
exposure of MVC relative to plasma as demonstrated in these studies lends further support 
for it being an ideal candidate for oral PrEP. However in comparison with TFV and its 
active metabolite TFV-DP, MVC half-life in tissue compartments is much shorter and thus 
will require consistent dosing and more patient compliance in terms of adherence.
For both the ARVs analyzed, drug concentrations varied widely between individual mice at 
some time points although the composite PK trends were similar. This is not unlike that 
observed in previous NHP and human studies wherein a wide degree of inter and intra-
subject variability was seen (Brown et al., 2011; Dumond et al., 2009; Dumond et al., 2007; 
Evans and Silvestri, 2013; Fennessey and Keele, 2013; Patterson et al., 2011; Vourvahis et 
al., 2008). While we used hu-mice with robust human cell reconstitution, their levels in 
individual mice could have partly played a role. However, this appears unlikely since wide 
variations in drug concentrations were seen in non-hu-mice as well.
With regard to the PK studies like these in the PrEP context, the importance of using hu-
mice versus non-hu-mice is apparent. This is illustrated by differences such as MVC plasma 
half-life being lower in hu-mice compared to non-hu mice. Additionally for compounds such 
as TFV which function intracellularly after phosphorylation, use of hu-mice harboring 
human cells is also more appropriate. Based on the overall data from above, hu-mice 
susceptible to HIV mucosal transmission can be exploited to assess ARV PK parameters. In 
addition to complementing results from NHP models, data derived in hu-mice on novel 
drugs would help inform more detailed subsequent macaque studies where appropriate. 
Drug concentrations determined to confer protection against HIV itself in hu-mice can be 
extrapolated to the human to inform HIV prevention doses of novel ARVs for prophylactic 
purposes.
Since the use of a single drug may not be adequate to confer full protection in a global 
setting, future oral HIV PrEP strategies will most likely involve a combination of ARVs 
with different mechanism of action for complete efficacy. However, whether the 
combinatorial ARVs would retain similar tissue distribution and overall kinetics compared 
to when applied singly needs to be determined. Such combinatorial studies can be conducted 
in hu-mice to define PK/PD parameters of various multi-drug regimen approaches to assess 
potential additive, synergistic and antagonistic effects between different classes of ARVs. In 
Veselinovic et al. Page 10













addition, adherence issues of PrEP use and efficacy can also be simulated in hu-mice to 
derive useful preclinical data (Adams et al., 2013). It is also clear from the present data and 
previous reports that drug distribution and kinetics in different tissues vary (Romano et al., 
2013; Thompson et al., 2013). This could be due to multiple factors which include target cell 
drug influx and efflux properties, differential mucosal expression and distribution of specific 
drug transporters and distinct expression of cytochrome P450 (CYP) and other drug 
metabolizing enzymes in mucosal compartments (Nicol et al., 2013; To et al., 2013). Such 
parameters can be experimentally evaluated in the humanized mouse model in the context of 
the human immune cell populations targeted by HIV. The preclinical knowledge gained 
from such in vivo studies addressing these questions will be very useful for more informed 
clinical trials of new PrEP strategies
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• First study in a hu-mouse model to determine pharmacokinetics of anti-HIV 
drugs in mucosal tissues
• In vivo analysis of anti-HIV drugs used for HIV pre-exposure prophylaxis
• Tenofovir and maraviroc showed higher levels of accumulation in mucosal 
tissues versus plasma
• Hu-mice are more appropriate for ARV drug PK analysis for HIV PrEP studies 
than non-hu mice
• Data from hu-mice PK studies will complement those from non-human primates
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Figure 1. PK analysis of orally administered TFV in hu- and non-hu mice
Mice were administered TFV by oral gavage (human equivalent dose 61.5 mg/kg) for 5 
days. Post-last dose, plasma and tissue samples were collected at different time points and 
drug concentrations were determined (ng/ml or ng/g). A1 (hu-mice), A2 (non-hu mice). 
Composite medians and interquartile ranges (IQR) for plasma, vaginal, rectal and intestinal 
tissue (colon). B1-E1 (hu-mice), B2-E2 (non-hu mice). Individual data points (n=5 hu-mice, 
n=3 non-hu mice) for plasma (B), vaginal (C), rectal (D) and intestinal tissue (colon) (E) 
with composite medians (IQR) shown.
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Figure 2. PK analysis of TFV DP in hu- and non-hu mice
TFV was gavaged as in Fig 1 above. Intracellular, diphosphorylated metabolite of TFV 
(TFV-DP) was detected and quantified in tissues at different times post-last dose. A1 (hu-
mice), A2 (non-hu mice). Composite median, IQR for TFV DP in rectal and intestinal tissue 
(colon). B1,C1 (hu mice), B2,C2 (non-hu mice). Individual data points shown (n=5 hu mice, 
n=3 non-hu mice) with composite median, IQR in rectal (B) and intestinal tissue (C).
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Figure 3. PK analysis of orally administered MVC in hu- and non-hu mice
Mice were administered MVC by oral gavage (human equivalent dose 62 mg/kg) for 5 days. 
Post-last dose, plasma and tissue samples were collected at different time points and drug 
concentrations were determined (ng/ml or ng/g). A1 (hu mice), A2 (non-hu mice). 
Composite medians and interquartile ranges (IQR) for plasma, vaginal, rectal and intestinal 
tissue (colon). B1-E1 (hu mice), B2-E2 (non-hu mice). Individual data points (n=3 hu-mice, 
n=5 non-hu mice) for plasma (B), vaginal (C), rectal (D) and intestinal tissue (colon) (E) 
with composite medians (IQR) shown.
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Figure 4. Tissue to blood plasma AUC24h ratios of TFV
Tissue to plasma ratios were calculated for AUC24h. On the y axis, 1 indicates a line of 
unity, where mucosal tissue exposure is similar to blood plasma. Values above the line of 
unity indicate higher drug exposure at mucosal sites compared to plasma. VT-vaginal tissue, 
RT-rectal tissue, IT-intestinal tissue (colon).
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Figure 5. Tissue to blood plasma AUC24h ratios of MVC
Tissue to plasma ratios were calculated for AUC24h. On the y axis, 1 indicates a line of 
unity, where mucosal tissue exposure is similar to blood plasma. Values above the line of 
unity indicate higher drug exposure at mucosal sites compared to plasma. VT-vaginal tissue, 
RT-rectal tissue, IT-intestinal tissue (colon).
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Table 1
PK parameters for Tenofovir and Tenofovir Diphosphate in humanized and non-humanized mice.
TFV (hu mice) Plasma Vaginal tissue Rectal tissue Intestinal tissue
Cmax 
* 1,990 729 56,732 74,677
Median (IQR) (898 – 3,310) (581 – 6,739) (21,746 – 164,561) (55,008 – 288,570)
Tmax 2h 2h 2h 2h
AUC 
† 11,251 14,946 1 × 106 1.43 × 106
t ½






Median (IQR) (336 – 6,466) (322 – 28,175)
Tmax NA / 2h 8h
AUC 
† NA / 70,194 172,167
t ½
‡ NA / 22.2 3.5
TFV (non-hu mice)
Cmax 
* 1,550 785 76,520 50,334
Median (IQR) (1,200-1,990) (224 - 819) (50,493 - 78,415) (38,112 - 72,930)
Tmax 2h 8h 8h 8h
AUC 
† 17,278 9,671 1.3 × 106 1 × 106
t ½
‡ 15 6.3 53 61.6
TFV-DP (non-hu mice)
Cmax 
* NA BLQ 198 119
Median (IQR)
Tmax NA / 24h 8h
AUC 





BLQ – below the limit of quantification; NA - not applicable
*
Median (interquartile range, IQR), ng/ml or ng/g
†




TFV-DP detected in 2 samples in humanized mice – once at 2h and once at 24h
□
no elimination phase
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Table 2
PK parameters for Maraviroc in humanized and non-humanized mice.
MVC (hu-mice) Plasma Vaginal tissue Rectal tissue Intestinal tissue
Cmax 
* 102 459 7,577 33,462
Median (IQR) (46 – 109) (228 – 659) (5,492.6 – 9,769) (31,958 – 36,819)
Tmax 4h 4h 4h 4h
AUC 
† 755 2,461 32,690 140,159
t ½
‡ 1 2.6 1.5 1.2
MVC (non-hu mice)
Cmax
* 113 1,764 3,785 18,194
Median (IQR) (43 - 797) (403 – 1,982) (2,329 – 8,512) (9,893 – 22,980)
Tmax 4h 4h 4h 4h
AUC 
† 3,280 11,239 69,301 134,883
t ½
‡ 20.1 3.7 2.9 2.7
*
Median (interquartile range, IQR), ng/ml or ng/g
†
Area under the curve (AUC)48h for plasma (ng * h/ml); AUC24h for tissues (ng * h/g)
‡
Half-life (t½, h)
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